Navigation Links
Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
Date:2/22/2013

ROCKVILLE, Md., Feb. 22, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that its flupirtine sublicensee, Meda AB (Meda), has received a green light from the Food and Drug Administration (FDA) to conduct a Phase II proof of concept study for the treatment of fibromyalgia as reported in Meda's 2012 year-end report. Meda has announced that the randomized, double-blind, placebo and active-controlled study of patients with fibromyalgia will be conducted at 25 clinics in the U.S.

In May 2010, the Company entered into an agreement with Sweden-based Meda granting exclusive sublicense to all of its patents and pending patents covering the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. Meda assumed all future development costs for the commercialization of flupirtine for fibromyalgia. Synthetic Biologics received an upfront payment and is entitled to future milestone payments, plus royalties.

"We are pleased to share Meda's update on the status of its clinical development program of flupirtine for fibromyalgia," stated Jeffrey Riley , Chief Executive Officer at Synthetic Biologics. "We believe Meda's experience with flupirtine outside of the U.S. will help bring this potential new class of treatment to the millions of people that suffer from fibromyalgia in the U.S."

About Fibromyalgia and Flupirtine

Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue, insomnia and mood symptoms. Fibromyalgia affects an estimated 3-6% of the population worldwide, including an estimated 10 million patients in the U.S. There are presently three products approved for this indication in
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
2. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
3. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
4. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
5. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
6. Synthetic Biologics Reports Second Quarter 2012 Financial Results
7. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. Employers Becoming Savvier About Biologics and Specialty Drugs
10. Pinnacle Biologics beantragt Zulassung neuer Indikationen in Deutschland und Frankreich
11. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Oct. 17, 2014  Training market researchers to ... success factor in today,s highly competitive global marketplace. ... organizations that effectively and efficiently produce high performing ... area. Effective training programs can ... recognition from internal clients by developing analysts who ...
(Date:10/17/2014)... 17, 2014 Research and Markets ... and Development Prospect of China Dialysis Market, 2014-2018" ... Based on the 2013 version, this update Report ... dialysis industry and the relevant effect in recent ... industry segmentations. Moreover, it analyzes Chinese private-owned hemodialysis ...
(Date:10/17/2014)... Oct. 17, 2014 The following is ... Policy: The Green Park Collaborative (GPC) ... and private payers, medical device and pharmaceutical companies, ... experts January 12, 2015 at its first ever ... weight loss treatments.  Participants will discuss study designs ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... 23, 2011 Varian Medical Systems (NYSE: VAR ... at the annual meeting of the American Society for Radiation ... financial community are invited to join senior management for a ... will host a meeting with management, beginning with breakfast at ...
... NEW YORK, Aug. 23, 2011 ITelagen, Inc., a leading ... that the company was named to the prestigious 2011 Inc. ... growing companies in America. This was the second ... 5000 and was placed on the list at position #2093, ...
Cached Medicine Technology:Varian Medical Systems Schedules Investor Meeting at ASTRO in Miami Beach, FL 2ITelagen Named to Prestigious 2011 Inc. 5000 List of Fastest-Growing Companies 2
(Date:10/20/2014)... Los Angeles, CA (PRWEB) October 20, 2014 ... embodies fitness expertise, nutritional coaching, corporate wellness programming, authorship, ... MS, CPT, is excited to announce the release of ... , After many years of coaching thousands of ... pioneering nutrition tracking app that does not require calorie ...
(Date:10/20/2014)... October 20, 2014 AttorneyOne.com, a recognized authority ... information from the FDA on Sit and Slim II ... not to purchase or use Sit and Slim II because ... II is promoted as weight loss product on various websites ... the market in 2010 for safety reasons, can significantly increase ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... October 20, 2014 Final Cut Pro X ... of the Citrus theme for FCPX filmmakers . , ... to describe the Citrus theme” Says Christina Austin, CEO of ... look so professional.” , Citrus comes with all the tools ... template are: four transitions for added style, a title screen ...
(Date:10/20/2014)... Punzoné , the first line of ultra-premium organic ... to celebrate this month. October marks Italian Heritage Month – ... of Americans of Italian heritage and Italians in America. October ... its favorite Italian cocktails and encourages everyone to enjoy its ... it is only in a glass. , Punzoné continues ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... identified in the blood of chronic sinusitis sufferers that ... disease, researchers say. , They used a sophisticated research ... proteins and found among 96 chronic sinusitis patients a ... can diagnose this disease with a totally objective test ...
... will support nonprofit organizations that address health care ... access and priorities in a four-state ... Group, the largest,health insurer in the Northwest/ Intermountain region, ... transforming health care in,the United States. The Regence Foundation ...
... who,has served as chairman and CEO of global safety ... Bill Lambert, MSA president and chief operating,officer, will ring ... on,Tuesday, April 15. The ceremonial bell ringing comes approximately ... as part of a planned management,succession, and turn over ...
... ,Pet Parent,s Day, e-Cards available on petinsurance.com, ... (VPI),the nation,s oldest and largest provider of pet ... -- this year, April 27 -- as National,Pet ... celebrating pet,caregivers. In the traditional spirit of a ...
... cells drive breast cancer formation, researcher says , , MONDAY, ... suggest breast cancer may arise from stem cells and ... may be a key to treatment. , Researchers from ... gene can flip open two known cancer pathways in ...
... at Thomas Jefferson University in Philadelphia are inching ... might help prevent the spread of pancreatic cancer. ... type of pressure-lowering drug called an angiotensin receptor ... cell death. , In earlier work in the ...
Cached Medicine News:Health News:Potential blood test for chronic sinusitis identified 2Health News:Newly Launched Regence Foundation to Help Transform Health Care and Influence the Nationwide Health Care Debate 2Health News:MSA's John Ryan III and Bill Lambert to Ring Closing Bell at New York Stock Exchange on Tuesday 2Health News:MSA's John Ryan III and Bill Lambert to Ring Closing Bell at New York Stock Exchange on Tuesday 3Health News:Veterinary Pet Insurance Launches National Pet Parent's Day 2Health News:Stem Cell Marker Controls Pair of Key Cancer Pathways 2Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2
... of Surgical Microscope Accessories includes digital camera ... cables, and fiberoptic retrofits. TTI Medical's patented ... 5,264,928) is the only adaptor that will ... the same adaptor body. It is fully ...
... Electronic Medical Record system. It stores patient chart ... and everything you would normally put in a ... Someone has to write them, file them, find ... Paper Charts get lost. They find their way ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
... WAVEFRONT ANALYZER provides a complete ... the entire eye. Real-time measurements ... aberrations in many different forms ... higher order aberrations, Zernike polynomials, ...
Medicine Products: